Responsiveness to Tocilizumab in Anti-Acetylcholine Receptor-Positive Generalized Myasthenia Gravis

Article Clinical Neurology

Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis The BeatMG Study

Richard J. Nowak et al.

Summary: This study suggests that rituximab is safe but unlikely to significantly reduce steroid use in patients with mild to moderate symptoms of AChR-Ab+ gMG.

NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis The RINOMAX Randomized Clinical Trial

Fredrik Piehl et al.

Summary: This study investigated the efficacy and safety of rituximab compared to placebo in the treatment of MG. The results showed that a single dose of 500 mg of rituximab was associated with a greater reduction in symptoms and decreased use of rescue medications compared to placebo.

JAMA NEUROLOGY (2022)

添加到收藏夹

Article Immunology

High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis

Akiyuki Uzawa et al.

Summary: Serum IL-6 levels are significantly higher in patients with anti-AChR antibody-positive MG and are correlated with disease activity levels, suggesting IL-6 could be a potential therapeutic target for MG.

JOURNAL OF NEUROIMMUNOLOGY (2021)

添加到收藏夹

Article Cell Biology

Sustained Systemic Levels of IL-6 Impinge Early Muscle Growth and Induce Muscle Atrophy and Wasting in Adulthood

Laura Pelosi et al.

Summary: IL-6 is a pleiotropic cytokine with different and opposite effects under healthy and pathologic conditions. It can stimulate muscle growth in healthy conditions but may lead to muscle wasting in pathological conditions. Increased plasma levels of IL-6 may be associated with stunted growth and muscle wasting.

CELLS (2021)

添加到收藏夹

Review Clinical Neurology

Advances and challenges in the treatment of myasthenia gravis

Christiane Schneider-Gold et al.

Summary: Myasthenia gravis is a chronic autoimmune disease with fluctuating muscle weakness. Standard immunomodulatory treatments may not be effective for all patients, leading to the need for new therapeutic approaches that target specific immune players. Emerging immunotherapies show promise in addressing the underlying mechanisms of MG and may offer potential benefits for patients with treatment-resistant MG.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

添加到收藏夹

Review Clinical Neurology

International Consensus Guidance for Management of Myasthenia Gravis 2020 Update

Pushpa Narayanaswami et al.

Summary: This study updated the 2016 formal consensus-based guidance for the management of myasthenia gravis, with updated recommendations on thymectomy and new recommendations on the use of rituximab, eculizumab, and methotrexate. The consensus guidance developed by international MG experts based on new evidence can provide direction for clinicians caring for MG patients worldwide.

NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology